wire - news in brief



Results 101 - 150 of 1656.

Pharmacology - Health - 23.03.2021
Novartis announces positive result of phase III study with radioligand therapy 177Lu-PSMA-617 in patients with advanced prostate cancer
Phase III VISION study with 177 Lu-PSMA-617 met both primary endpoints, significantly improving overall survival (OS) and radiographic progression-free survival (rPFS) in patients with PSMA-positive

Health - Pharmacology - 18.03.2021
Learning from the dead to help the living
Learning from the dead to help the living
The lungs are the primary, but not the only target of Covid-19. Early in the pandemic, Basel researchers were among the first to venture to perform autopsies on deceased Covid-19 patients, making important contributions to our understanding of the new infectious disease. Professor Alexandar Tzankov of the University of Basel is leading a research project highlighting the effects of the virus on the body's tissues and organs.

Pharmacology - Health - 15.03.2021
New Zolgensma data demonstrate age-appropriate development when used early, real-world benefit in older children and durability 5+ years post-treatment
Children with SMA treated presymptomatically achieved age-appropriate motor milestones including sitting, standing and walking; required no ventilatory or feeding tube support; and had no serious, tr

Health - Pharmacology - 26.02.2021
EMA issues advice on casirivimab and imdevimab antibody cocktail for the treatment of mild-to-moderate COVID-19
CHMP has completed a review of available data for investigational antibody cocktail casirivimab and imdevimab (REGN-COV2) to be considered for the treatment of confirmed COVID-19   CHMP scientific op

Pharmacology - Health - 26.02.2021
Novartis Cosentyx gains EU label update for first-of-its-kind MAXIMISE data in axial manifestations of psoriatic arthritis
Cosentyx (secukinumab) is the first biologic with proven efficacy in all 6 key manifestations of psoriatic arthritis (PsA), and the only biologic with fast and lasting relief of axial manifestations of PsA in a dedicated trial 1,2 ,3 .

Health - Pharmacology - 25.02.2021
Roche announces results from Evrysdi (risdiplam) study in infants with Type 1 spinal muscular atrophy (SMA) published in New England Journal of Medicine
FIREFISH Part 1 data show treatment with Evrysdi at 12 months helped 90% of these infants survive without permanent ventilation and 33% sit without support, a key motor milestone not normally seen in

Pharmacology - Health - 16.02.2021
Novartis Entresto granted expanded indication in chronic heart failure by FDA
Entresto is the first and only therapy approved in the US to treat patients diagnosed with guideline-defined heart failure to include both those with heart failure with reduced ejection fraction (HFr

Health - Pharmacology - 10.02.2021
A very aggressive cancer defeated in three months
A very aggressive cancer defeated in three months
A team from the University of Geneva and HUG managed to save a woman whose aggressive cancer left her with only five months to live.

Pharmacology - Health - 08.02.2021
Novartis receives FDA Breakthrough Therapy designations for investigational STAMP inhibitor asciminib (ABL001) in chronic myeloid leukemia
Designation in patients with chronic myeloid leukemia (CML) resistant or intolerant to prior treatments based on positive data from pivotal Phase III ASCEMBL trial evaluating asciminib, an investigat

Pharmacology - Health - 29.01.2021
Novartis receives positive CHMP opinion for Kesimpta * (ofatumumab), a self-administered treatment for adult patients with relapsing multiple sclerosis
  Kesimpta is a targeted B-cell therapy that delivers superior efficacy with a similar safety and tolerability profile compared with teriflunomide, a first-line treatment in MS 1 CHMP opinion is base

Health - Pharmacology - 28.01.2021

Health - Pharmacology - 25.01.2021
A treatment for every kind of cancer
A treatment for every kind of cancer
Researchers from the University of Basel have identified cells in the immune system that are able to attack a wide range of cancer cells.

Health - Pharmacology - 25.01.2021
A new ’double’ antibody that protects against Covid-19 and its variations discovered in Ticino
The Institute for Research in Biomedicine (IRB, affiliated to USI Universitą della Svizzera italiana, has developed a second-generation 'double antibody' that protects from SARS-CoV-2, the virus causing COVID-19, and all its tested variants.

Pharmacology - Health - 14.01.2021
Novartis ligelizumab (QGE031) receives FDA Breakthrough Therapy designation for patients with chronic spontaneous urticaria (CSU)
Ligelizumab is the first treatment to receive FDA Breakthrough Therapy designation in chronic spontaneous urticaria (CSU) in patients with an inadequate response to H1-antihistamines 1   Currently th

Pharmacology - Health - 12.01.2021
Second COVID-19 vaccine approved for Switzerland
On 12 January 2021 Swissmedic, the Swiss agency for the authorisation and supervision of therapeutic products, approved the second COVID-19 vaccination for the Swiss market.

Health - Pharmacology - 05.01.2021
New Ebolavirus treatment sees the light thanks to basic research performed in Ticino
While populations around the world are being vaccinated against SARS-CoV-2, the U.S. Food and Drug Administration has announced the approval of a treament against another well-known virus, much less widespread but extremely lethal: Ebola.

Pharmacology - Health - 19.12.2020
Swissmedic grants authorisation for the first COVID-19 vaccine in Switzerland
Vaccine from Pfizer/BioNTech authorised in the rolling review procedure after close scrutiny of the risks and benefits Swissmedic has authorised the vaccine from Pfizer/BioNTech.

Life Sciences - Pharmacology - 18.12.2020
A weather station for epileptic seizure
A weather station for epileptic seizure
The unpredictability of epileptic seizures is a severe handicap for patients.

Pharmacology - Health - 16.12.2020
Novartis investigational oral therapy iptacopan (LNP023) receives FDA Breakthrough Therapy Designation for PNH and Rare Pediatric Disease Designation for C3G
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare and life-threatening blood disorder, resulting in debilitating symptoms that can impact patients' quality of life 1-3 C3 glomerulopathy (C3G) is a

Pharmacology - Health - 16.12.2020
Novartis announces positive FDA Advisory Committee recommendation for use of Entresto to treat patients with HFpEF
The Committee voted 12 to 1 that the data presented support the use of Entresto in treatment of patients with heart failure with preserved ejection fraction (HFpEF) Potential Q1 2021 sNDA approval co

Health - Pharmacology - 15.12.2020
New synthetic molecule can kill the flu virus
New synthetic molecule can kill the flu virus
Scientists have developed a synthetic molecule capable of killing the virus that causes influenza. They hope their discovery will lead to an effective drug treatment.

Pharmacology - Health - 15.12.2020
Novartis reports positive topline results from second Phase III trial of Beovu in patients with diabetic macular edema
In Phase III KESTREL study, Beovu (brolucizumab 6 mg) achieved its primary endpoint of non-inferiority to aflibercept 2 mg in change in best-corrected visual acuity (BCVA) at year one (week 52) 1 In